JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
138.76
+0.64 (+0.46%)
At close: 4:00PM EDT

138.76 0.00 (0.00%)
After hours: 4:52PM EDT

Stock chart is not supported by your current browser
Previous Close138.12
Open138.35
Bid138.73 x 1000
Ask138.99 x 900
Day's Range137.49 - 138.95
52 Week Range118.62 - 148.99
Volume5,084,219
Avg. Volume6,196,504
Market Cap368.416B
Beta (3Y Monthly)0.68
PE Ratio (TTM)25.72
EPS (TTM)5.40
Earnings DateJul 16, 2019
Forward Dividend & Yield3.80 (2.69%)
Ex-Dividend Date2019-05-24
1y Target Est148.12
Trade prices are not sourced from all markets
  • Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
    Zacks5 hours ago

    Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $138.76, moving +0.46% from the previous trading session.

  • Reuters8 hours ago

    Congo wants more use of Merck vaccine rather than J&J newcomer - minister

    Democratic Republic of Congo called on Wednesday for Merck's experimental Ebola vaccine to be fully licensed to facilitate its use in the Ebola-hit country, while saying Johnson & Johnson's rival drug would complicate matters. Both vaccines are experimental drugs that can be used under strictly controlled research protocols but Merck's has been used throughout the outbreak and has proven highly effective, the World Health Organization (WHO) says. Congolese Health Minister Oly Ilunga Kalenga told reporters in Geneva that the government would roll out a "geographic ring" vaccination strategy in the coming days.

  • Benzinga15 hours ago

    The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...

  • West Chester company to eliminate 76 jobs
    American City Business Journalsyesterday

    West Chester company to eliminate 76 jobs

    Medical Device company DePuy Synthes is eliminating 76 jobs in Chester County. A Worker Adjustment and Retraining Notification Act notice the orthopedic and neurosurgery products developer filed last week with the Pennsylvania Department of Labor and Industry stated its DePuy Synthes Sales Inc. unit will be eliminating its extremities sales organization in West Chester. Asked about the job reduction, DePuy Synthes issued a statment that read: "DePuy Synthes recently made a strategic decision to move away from a dedicated extremities sales force as part of an ongoing assessment of resource utilization and optimization, resulting in an overall reduction in positions.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix

  • Zacks Small Cap Research2 days ago

    ARWR: ARO-AAT Ph 2/3 Detailed, Could Serve as FDA Pivotal Study. Continued Broad-Based Pipeline Progress

    This includes presentations at the EASL International Liver Congress in April from preclinical long-term data from the previous-generation AAT as well as interim results of JNJ-3989 (ARO-HBV) among 40 patients at 24+ weeks follow-up in their ongoing Phase 1/2 study. The JNJ-3989 Phase 1/2 study (chronic hepatitis B) continues and was recently expanded to include a triple combination cohort (cohort 12), which along with JNJ-3989, will include additional undisclosed agents chosen by Janssen. Management indicated that this triple combination cohort could generate data relatively quickly – which will be one of several near-term development-related announcements that we anticipate.

  • Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs
    Zacks2 days ago

    Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs

    Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs

  • Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices
    MarketWatch2 days ago

    Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices

    The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.

  • This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
    Zacks3 days ago

    This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

  • AbbVie's Brain Cancer Candidate Fails in Phase III Study
    Zacks3 days ago

    AbbVie's Brain Cancer Candidate Fails in Phase III Study

    AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.

  • After J&J sale, Cambridge investor sets sights on $175M raise for new medtech VC firm
    American City Business Journals3 days ago

    After J&J sale, Cambridge investor sets sights on $175M raise for new medtech VC firm

    With the launch of his new company, Miraki Innovation, Velis hopes to expand his reach in medtech, founding more companies in healthcare diagnostics, infectious disease and robotics that will follow Auris’ lead.

  • Reuters4 days ago

    Modi’s jobs deficit - J&J’s largest India plant idle three years after completion

    PENJERLA/NEW DELHI, India (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India. Two sources familiar with J&J's operations in India and one state government official told Reuters production at the plant, at Penjerla in Telangana state, never began because of a slowing in the growth in demand for the products.

  • Reuters4 days ago

    Modi’s jobs deficit: J&J’s largest India plant idle 3 years after completion

    PENJERLA/NEW DELHI, India May 19 (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India. Two sources familiar with J&J's operations in India and one state government official told Reuters production at the plant, at Penjerla in Telangana state, never began because of a slowing in the growth in demand for the products.

  • Benzinga4 days ago

    Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More

    Benzinga has examined prospects for many investor favorite stocks over the past week. Bearish calls included biotechs and a recent IPO. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.

  • 6 Things Johnson & Johnson Wants You to Know About Its Pharmaceuticals
    Motley Fool4 days ago

    6 Things Johnson & Johnson Wants You to Know About Its Pharmaceuticals

    Here's what management wants investors to know about the future of the company's pharmaceutical segment.

  • Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout
    Investor's Business Daily5 days ago

    Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout

    Dow Jones component Johnson & Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday. MeiraGTx is working on treatments for eye diseases.

  • Reuters5 days ago

    Exclusive: FBI targets Johnson & Johnson, Siemens, GE, Philips in Brazil graft case - Sources

    The U.S. FBI is investigating corporate giants Johnson & Johnson, Siemens AG, General Electric Co and Philips for allegedly paying kickbacks as part of a scheme involving medical equipment sales in Brazil, two Brazilian investigators have told Reuters. Brazilian prosecutors suspect the companies channelled illegal payoffs to government officials to secure contracts with public health programs across the South American country over the past two decades. Brazilian authorities say more than 20 companies may have been part of a "cartel" that paid bribes and charged the government inflated prices for medical gear such as magnetic resonance imaging machines and prosthetics.

  • Exclusive: FBI targets Johnson & Johnson, Siemens, GE, Philips in Brazil graft case - sources
    Reuters5 days ago

    Exclusive: FBI targets Johnson & Johnson, Siemens, GE, Philips in Brazil graft case - sources

    The U.S. FBI is investigating corporate giants Johnson & Johnson, Siemens AG, General Electric Co and Philips for allegedly paying kickbacks as part of a scheme involving medical equipment sales in Brazil, two Brazilian investigators have told Reuters. Brazilian prosecutors suspect the companies channeled illegal payoffs to government officials to secure contracts with public health programs across the South American country over the past two decades. Brazilian authorities say more than 20 companies may have been part of a "cartel" that paid bribes and charged the government inflated prices for medical gear such as magnetic resonance imaging machines and prosthetics.

  • Reuters5 days ago

    U.S. FDA labels J&J surgical staplers' recall as severest

    The recall, initiated early April by Ethicon, covers 92,496 surgical staplers and is now labeled as "Class-1" - the strictest form of recall issued by FDA, where use of faulty devices may cause serious injury or death. J&J's Ethicon unit confirmed serious injuries to two patients, related to the use of the recalled product, the FDA said.

  • CNBC6 days ago

    Your first trade for Friday, May 17

    The "Fast Money" traders share their first moves for the market open.

  • Johnson & Johnson to Participate in Bernstein's 35th Annual Strategic Decisions Conference
    PR Newswire6 days ago

    Johnson & Johnson to Participate in Bernstein's 35th Annual Strategic Decisions Conference

    NEW BRUNSWICK, N.J. , May 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in Bernstein's 35 th Annual Strategic Decisions Conference on Thursday, May 30 , at the Grand Hyatt, New ...

  • Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
    Zacks6 days ago

    Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

    FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

  • Did Geron's Big Announcement Just Go Unnoticed?
    Motley Fool6 days ago

    Did Geron's Big Announcement Just Go Unnoticed?

    Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.